Core Viewpoint - Immix Biopharma, Inc. (IMMX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Revisions - The company is projected to earn -$0.72 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 19.1% [8]. - Over the past three months, the Zacks Consensus Estimate for Immix Biopharma has increased by 20.9%, indicating a positive trend in earnings estimates [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 positions Immix Biopharma in the top 20% of Zacks-covered stocks, suggesting a strong potential for near-term price movement [10]. Impact of Institutional Investors - Changes in earnings estimates are closely correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [4]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional buying or selling, which influences stock prices [4]. Business Outlook - The rising earnings estimates and the subsequent rating upgrade for Immix Biopharma suggest an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively to this trend [5].

Clinical Development - Immix Biopharma's lead candidate, CAR-T NXC-201, is currently in Phase 1b/2a clinical trials for relapsed/refractory AL Amyloidosis, with 76 patients treated as of June 2024[114]. - NXC-201 has shown a 100% overall response rate and a 70% complete response rate in a presentation covering 10 patients at the ASH meeting in December 2023[115]. - The FDA granted Orphan Drug Designation to NXC-201 for AL Amyloidosis in September 2023, providing 7 years of exclusivity upon first approval[115]. - The European Commission granted orphan drug designation to NXC-201 in February 2024, offering 10 years of market exclusivity once authorized in the EU[117]. - Nexcella has committed to funding NXC-201 clinical trials in Israel for an estimated total cost of approximately $13 million over four years[123]. - Immix Biopharma's other programs include NXC-201 for autoimmune diseases, targeting a combined annual market size of $25 billion[118]. - The company was awarded an $8 million grant from the California Institute for Regenerative Medicine for clinical development of NXC-201, with funds expected to begin in September 2024[139]. Financial Performance - Immix Biopharma has incurred recurring losses primarily due to research and development activities, with significant expenses expected to continue as product candidates advance[119]. - General and administrative expenses increased to $4,819,821 for the six months ended June 30, 2024, compared to $2,713,201 for the same period in 2023, reflecting a 77.5% increase[133]. - Research and development expenses rose to $5,472,808 for the six months ended June 30, 2024, compared to $3,528,264 for the same period in 2023, marking a 55.0% increase[134]. - Net loss for the six months ended June 30, 2024, was $9,736,914, compared to $6,096,244 for the same period in 2023, representing a 59.0% increase[135]. - Net cash used in operating activities was $9,082,817 for the six months ended June 30, 2024, compared to $5,607,342 for the same period in 2023[142]. - Net cash provided by financing activities was $15,948,567 for the six months ended June 30, 2024, compared to $4,810,576 for the same period in 2023[144]. - As of June 30, 2024, the company had total working capital of $23.4 million[138]. Corporate Actions - The company merged with its subsidiary Nexcella on May 20, 2024, with Nexcella's assets and operations now part of Immix Biopharma[120]. - The company has entered into a Research and License Agreement with Hadasit and BIRAD, involving an upfront fee of $1.5 million and additional payments totaling approximately $13 million through September 2026[122]. - The company entered into an ATM Sales Agreement on July 14, 2023, allowing for the sale of up to $4,200,000 worth of common stock until the public float reaches $75 million[125]. - From July 14, 2023, to February 5, 2024, the company sold 328,136 common shares for net proceeds of $1,091,887 after offering expenses[126]. - On February 5, 2024, the company completed a public offering of 5,535,055 shares at a price of $2.71 per share, resulting in net proceeds of $13,565,760[128]. Regulatory and Compliance - The company intends to rely on exemptions as an "emerging growth company" until it reaches total annual gross revenues of $1.235 billion or more[147]. - Financial statements are prepared in accordance with U.S. GAAP, requiring management to make estimates and judgments that may materially affect reported amounts[148]. - There have been no material changes to the company's critical accounting policies and estimates since the 2023 Form 10-K[148].

LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. ("Nexcella", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Nexcella an $8 million CLIN2 grant award to support clinical development of its chimeric antigen receptor T cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis. "AL amylo ...

LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us", "IMMX") (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy. The NEXICART-2 study is intended to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL A ...

The IMMX Team will be available for institutional investor meetings during the Contacts Mike Moyer LifeSci Advisors mmoyer@lifesciadvisors.com LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Immix Biopharma, Inc. (ImmixBio) (Nasdaq ...

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. About Immix Biopharma, Inc. This press release contains forward-looking statements regarding Immix Biopharma, Inc., including the potential benefits of our initial product candidates, ...

LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development ...

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond Best responder duration of response was 28.0 months with response ongoing as of May 10, 2024U.S. prevalence of relapsed/refractory AL Amyloidosis is growing 12 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Not applicable (Former na ...

European Orphan Drug Designation ("ODD") qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX) ...